Amarin Corporation plc (ADR) (AMRN) was Initiated by Citigroup to “Buy” and the brokerage firm has set the Price Target at $5. Citigroup advised their investors in a research report released on Oct 19, 2016.
Many Wall Street Analysts have commented on Amarin Corporation plc (ADR). Cantor Fitzgerald Initiated Amarin Corporation plc (ADR) on Oct 5, 2016 to “Buy”, Price Target of the shares are set at $6.
On the company’s financial health, Amarin Corporation plc (ADR) reported $-0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.13. The company had revenue of $32.81 million for the quarter, compared to analysts expectations of $29.30 million. The company’s revenue was up 85.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.15 EPS.
Amarin Corporation plc (ADR) closed down -0.03 points or -1.00% at $2.96 with 23,26,296 shares getting traded on Friday. Post opening the session at $3, the shares hit an intraday low of $2.94 and an intraday high of $3.02 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Feb 3, 2016, John F Thero (CEO) purchased 25,000 shares at $1.37 per share price.
Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarin’s lead product Vascepa (icosapent ethyl) capsules are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers as well as regional wholesalers and specialty pharmacy providers who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.